Simon Kohl

R&D

In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.

News

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.